THE ROLE OF NEUTROPHIL EXTRACELLULAR TRAPS IN TUMOR MICROENVIRONMENT MODULATION AND PROGNOSTIC SIGNIFICANCE OF GLIOBLASTOMA
DOI:
https://doi.org/10.69723/njms.04.02.0550Keywords:
Tumor microenvironment, Neutrophil extracellular traps, Prognosis, GlioblastomaAbstract
BACKGROUND: The effects of neutrophil extracellular traps (NET) on cell invasion, inflammation, metastasis, and resistance to treatment are profound. However, little is known about NET's involvement in glioblastoma.
OBJECTIVE: The objective was to investigate the expression patterns of NET, their relationships to the tumor microenvironment (TME), and their significance for the survival of glioblastoma patients.
METHODOLOGY: The in-silico study was conducted from June 2023 to December 2024. Gene expression patterns and clinical data were obtained from the UCSC Xena database for patients diagnosed with glioblastoma. NET-related gene expression profiles were validated in U251 glioblastoma cells and human astrocytes, and these results were used to construct prognostic signatures.
RESULTS: Patients with low NET values compared to individuals with high NET scores had lower overall survival (OS, P<0.001). A high NET score was linked to different TMB and neutrophil-related paths. The NET score correlated greatly with both OS and treatment response after confirming in vitro research.
CONCLUSIONS: The NET score system represents a novel, clinically relevant tool for assessing prognostic risk in glioblastoma multiforme (GBM). Our findings suggest that NETs could serve as both biomarkers and therapeutic targets, offering new avenues for personalized treatment strategies in glioblastoma.
KEYWORDS: Tumor microenvironment; Neutrophil extracellular traps; Prognosis; Glioblastoma
References
Batash R, Asna N, Schaffer P, Francis N, Schaffer M. Glioblastoma multiforme, diagnosis and treatment; recent literature review. Curr Med Chem. 2017;24(27):3002–9. https://doi.org/10.2174/0929867324666170516123206
Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol. 2018;20(Suppl 4):iv1–86. https://doi.org/10.1093/neuonc/noy131
Irshad HA, Rizvi SBA, Bajwa MH, Khalid MU, Shah MM, Enam SA. Epidemiology of glioblastoma in Pakistan: a secondary analysis of the Pakistan Brain Tumor Epidemiology Study (PBTES). J Neurooncol. 2025;171(2):455–62. https://doi.org/10.1007/s11060-024-04872-3
Taylor JW, Dietrich J, Gerstner ER, Norden AD, Rinne ML, Cahill DP, et al. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol. 2015;121:557–63. https://doi.org/10.1007/s11060-014-1667-z
Usama SM, Jiang Z, Pflug K, Sitcheran R, Burgess K. Conjugation of Dasatinib with MHI‐148 has a significant advantageous effect in viability assays for glioblastoma cells. ChemMedChem. 2019;14(17):1575–9. https://doi.org/10.1002/cmdc.201900356
Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, et al. Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. J Neurooncol. 2018;136:79–86. https://doi.org/10.1007/s11060-017-2624-4
Jo Y, Kim EH, Sai S, Kim JS, Cho JM, Kim H, et al. Functional biological activity of sorafenib as a tumor-treating field sensitizer for glioblastoma therapy. Int J Mol Sci. 2018;19(11):3684. https://doi.org/10.3390/ijms19113684
Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med. 2019;25(3):470–6. https://doi.org/10.1038/s41591-018-0339-5
Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 2018;20(5):674–86. https://doi.org/10.1093/neuonc/nox208
Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(7):1003–10. https://doi.org/10.1001/jamaoncol.2020.1024
Da Ros M, De Gregorio V, Iorio AL, Giunti L, Guidi M, De Martino M, et al. Glioblastoma chemoresistance: the double play by microenvironment and blood-brain barrier. Int J Mol Sci. 2018;19(10):2879. https://doi.org/10.3390/ijms19102879
Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–95. https://doi.org/10.1016/j.immuni.2013.10.003
Sollberger G, Tilley DO, Zychlinsky A. Neutrophil extracellular traps: the biology of chromatin externalization. Dev Cell. 2018;44(5):542–53. https://doi.org/10.1016/j.devcel.2018.01.019
Demers M, Krause DS, Schatzberg D, Martinod K, Voorhees JR, Fuchs TA, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A. 2012;109(32):13076–81. https://doi.org/10.1073/pnas.1200419109
Ham SW, Jeon HY, Jin X, Kim EJ, Kim JK, Shin YJ, et al. TP53 gain-of-function mutation promotes inflammation in glioblastoma. Cell Death Differ. 2019;26(3):409–25. https://doi.org/10.1038/s41418-018-0126-3
De Leo A, Ugolini A, Veglia F. Myeloid cells in glioblastoma microenvironment. Cells. 2020;10(1):18. https://doi.org/10.3390/cells10010018
Shariati A, Nemati R, Sadeghipour Y, Yaghoubi Y, Baghbani R, Javidi K, et al. Mesenchymal stromal cells (MSCs) for neurodegenerative disease: a promising frontier. Eur J Cell Biol. 2020;99(6):151097. https://doi.org/10.1016/j.ejcb.2020.151097
Khan S, Mittal S, McGee K, Alfaro-Munoz KD, Majd N, Balasubramaniyan V, et al. Role of neutrophils and myeloid-derived suppressor cells in glioma progression and treatment resistance. Int J Mol Sci. 2020;21(6):1954. https://doi.org/10.3390/ijms21061954
Locarno CV, Simonelli M, Carenza C, Capucetti A, Stanzani E, Lorenzi E, et al. Role of myeloid cells in the immunosuppressive microenvironment in gliomas. Immunobiology. 2020;225(1):151853. https://doi.org/10.1016/j.imbio.2019.10.002
Yee PP, Wei Y, Kim SY, Lu T, Chih SY, Lawson C, et al. Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression. Nat Commun. 2020;11(1):5424. https://doi.org/10.1038/s41467-020-19193-y
König CS, Monteiro RQ. Neutrophil extracellular traps (NETs) promote pro-metastatic phenotype in human breast cancer cells through epithelial–mesenchymal transition. Cancers (Basel). 2020;12(6):1542. https://doi.org/10.3390/cancers12061542
Groblewska M, Litman-Zawadzka A, Mroczko B. The role of selected chemokines and their receptors in the development of gliomas. Int J Mol Sci. 2020;21(10):3704. https://doi.org/10.3390/ijms21103704
Sampson JH, Gunn MD, Fecci PE, Ashley DM. Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer. 2020;20(1):12–25. https://doi.org/10.1038/s41568-019-0224-7
Kim G, Ko YT. Small molecule tyrosine kinase inhibitors in glioblastoma. Arch Pharm Res. 2020;43:385–94. https://doi.org/10.1007/s12272-020-01232-3
Zhang N, Wei L, Ye M, Kang C, You H. Treatment progress of immune checkpoint blockade therapy for glioblastoma. Front Immunol. 2020;11:592612. https://doi.org/10.3389/fimmu.2020.592612
Tomaszewski W, Sanchez-Perez L, Gajewski TF, Sampson JH. Brain tumor microenvironment and host state: implications for immunotherapy. Clin Cancer Res. 2019;25(14):4202–10. https://doi.org/10.1158/1078-0432.CCR-18-1627
Zhang Y, Hu Y, Ma C, Sun H, Wei X, Li M, et al. Diagnostic, therapeutic predictive, and prognostic value of neutrophil extracellular traps in patients with gastric adenocarcinoma. Front Oncol. 2020;10:1036. https://doi.org/10.3389/fonc.2020.01036
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Sampana Fatima, Delima Maria, Fazlina Shaid, Muhammad Aizad khurram
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purposes. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
.png)
